The once white-hot investing guru has cooled off considerably, but some of her picks are ready to fire up again. Read More...
Motley Fool
This Growth Stock’s Jaw-Dropping Run-Up Is Smashing Tesla’s
Tesla stock might’ve made investors rich over the last few years, gaining more than 599.9% since late 2019, but 2022 has been a rough year for the company, with its shares losing slightly more than half their value amid a punishing bear market. In contrast, a little-known biotech called Catalyst Pharmaceuticals (NASDAQ: CPRX) gained 303% in 2022, and there’s reason to believe that there’s still plenty of upside to come. In fact, the company is ripe for a purchase, and there’s reason to believe it might continue to smash Tesla’s return in 2023 and beyond.
